The Arthur and Linda Gelb Center for Translational Research

With the completion of the human genome and the ongoing scientific effort toward understanding the genetic abnormalities underlying the development and progression of prostate cancer comes the promise of the identification of many new anticancer targets. As new therapies become available, it is important that we shorten the time required to evaluate and optimize such new agents. To this end, a new paradigm in prostate cancer drug testing is required. Specifically, in addition to using radiographic or serum markers as indirect measures of efficacy, we seek to assess drug efficacy based on the study of tumor cells derived from patients during treatment by any given therapeutic agent.

The specific aims of the Gelb Center are to develop a clinical samples banking system in which patient samples (such as tumors, serum, and other cellular samples) and clinical data are stored, and to develop an infrastructure capable of supporting the sophisticated molecular analysis of tissue samples.

Learn more about the research studies and the CRIS databases.